Beneficial effect of trimetazidine on folic acid‐induced acute kidney injury in mice: Role of HIF‐1α/HO‐1

Abstract Acute kidney injury (AKI) is a complex syndrome associated with a decrease in renal function and a significant impact on patient outcomes. Injection of folic acid (FA) in mice is used for studying the pathogenesis of AKI. This study investigated the impact of trimetazidine (a metabolic modulator‐antianginal drug; TMZ), against FA‐induced AKI. AKI was induced by FA (250 mg/kg, ip) in mice. Two doses of TMZ were administered orally for 10 days. Administration of TMZ at a high dose (20 mg/kg) exhibited significant decreases in the renal somatic index (RSI), serum levels of lactate dehydrogenase (LDH), creatinine (Cr), blood urea nitrogen (1), and proteins level in urine. Moreover, TMZ significantly increased creatinine clearance (CCr), serum albumin, urine creatinine, and urine urea levels. This improvement in markers of kidney damage was associated with marked renal antioxidant effects (↓NO and ↓lipid peroxidation, normalized reduced glutathione (GSH) level and superoxide dismutase (SOD) activity, and increased HIF‐1α/HO‐1 level). Furthermore, TMZ significantly decreased FA‐induced expression of MPO and inflammatory cytokine IL‐18, TNF‐α, and NF‐κB p65 subunit. Renal apoptosis, along with apoptotic markers, were enhanced by FA injection and suppressed by TMZ administration (↓Caspase‐3, ↓Bax, and ↑Bcl2 expression). Finally, TMZ amended FA‐induced histopathological changes in kidneys. By mitigating functional alteration, oxidative stress, and preventing the development of inflammatory and apoptosis signals, TMZ provides dose‐dependent defense against FA‐induced AKI mainly via stimulation of hypoxia‐inducible factor‐1 alpha (HIF‐1α)/heme oxygenase‐1 (HO‐1) pathway.